Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[212Pb\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.

Trial Details

NCT ID
NCT07278479
Phase
PHASE1 / PHASE2
Sponsor
Molecular Partners AG
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • [212Pb]Pb-MP0712
  • [203Pb]Pb-MP0712
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Glen Burnie, Maryland, United States|39.16261,-76.62469
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • Princeton, New Jersey, United States|40.34872,-74.65905
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Age ≥ 18 years old
  • Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung
  • SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based thera…
  • LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →